1
Jeffrey A Ledbetter, Lisa K Gilliland, Martha S Hayden, Peter S Linsley, Jurgen Bajorath, H Perry Fell: Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell. Bristol Myers Squibb Co, Audrey F Sher, October 17, 2000: US06132992 (112 worldwide citation)

The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first bi ...


2
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath: Antibodies against human CD40. Bristol Myers Squibb Co, Christopher A Klein, Audrey F Sher, April 18, 2000: US06051228 (81 worldwide citation)

The Applicants have discovered a novel antibody, more specifically a chimerized anti-human CD40 monoclonal antibody, which blocks the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent ant ...


3
Jeffrey A Ledbetter, Lisa K Gilliland, Martha S Hayden, Peter S Linsley, Jurgen Bajorath, H Perry Fell: Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell. Bristol Myers Squibb Company, Merchant Gould Smith Edell Welter & Schmidt, June 10, 1997: US05637481 (77 worldwide citation)

The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first bi ...


4
Peter S Linsley, Jeffrey A Ledbetter, Jurgen Bajorath, Robert Peach, William Brady: CTLA4/CD28Ig hybrid fusion proteins and uses thereof. Bristol Myers Squibb Company, Mandel & Adriano, July 18, 2000: US06090914 (60 worldwide citation)

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins including CTLA4/CD28 ...


5
Anthony W Siadak, Diane L Hollenbaugh, Lisa K Gilliland, Marcia L Gordon, Jurgen Bajorath, Alejandro A Aruffo: Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy. Bristol Myers Squibb Company, Christopher A Klein, Brian W Poor, Joseph M Sorrentino, March 2, 1999: US05876950 (34 worldwide citation)

The present invention provides monoclonal antibodies, antigen binding fragment and recombinant binding proteins specific for human gp39. These antibodies are specific for at least eight different epitopes on gp39. Hybridomas secreting specific antibodies which bind to these epitopes are also provide ...


6
Robert J Peach, Joseph Roy Naemura, Peter S Linsley, Jurgen Bajorath: Soluble CTLA4 mutant molecules. Bristol Myers Squibb Co, Audrey F Sher, Sarah B Adriano, August 22, 2006: US07094874 (29 worldwide citation)

The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino ac ...


7

8
Christian P Larsen, Thomas C Pearson, Andrew B Adams, Robert J Peach, Peter S Linsley, Joseph Roy Naemura, Jurgen Bajorath: Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules. Bristol Myers Squibb Company, Mandel & Adriano, December 4, 2007: US07304033 (28 worldwide citation)

The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.


9
Robert Cohen, Robert James Peach, David Hagerty, Suzette Carr, Jean Claude Becker, Peter S Linsley, Joseph Roy Naemura, Jurgen Bajorath: Methods for treating immune system diseases using a soluble CTLA4 molecule. Bristol Myers Squibb Company, Audrey Sher, Nickki L Parlet, November 25, 2008: US07455835 (21 worldwide citation)

The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.


10
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath, William D Huse, Herren Wu, Jeffry D Watkins: Antibodies against human CD40. Joan E Switzer, November 6, 2001: US06312693 (21 worldwide citation)

The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transp ...